Homepage
Healthcare · Biotechnology · United States · Updated May 11, 1:58pm
$17.96
Price
$495.2M
Market Cap
41
Employees
1.20
Beta
Joshua T. Brumm
CEO
Business Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Business History
Price Overview
Last updated: May 11, 2026 1:58pm (just now)$17.96
-0.80 (-4.26%)
Day Range
$17.78 – $19.81
52-Week Range
$8.72 – $28.00
50-Day MA
$16.72
200-Day MA
$13.49
Volume
250,217.00
Analyst Price Targets
Low
$29.00
Consensus
$33.00
High
$35.00
(5 analysts)
Share Structure
Outstanding
27,571,900.00
Float
21,313,106.00
Free Float
77.3%
Normal free float
— 77.3% of shares trade freely, ~22.7% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.22
Stock Price: $17.96
EPS (Diluted): -14.78
EPS (Diluted): -14.78
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.61
Stock Price: $17.96
Total Equity: $203.01M
Shares: 10,413,649
Total Equity: $203.01M
Shares: 10,413,649
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.94
Market Cap: $495.19M
Total Debt: $1.64M
Cash: $213.19M
EBITDA: -$149.67M
Total Debt: $1.64M
Cash: $213.19M
EBITDA: -$149.67M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$88.0M
Market Cap: $495.19M
Total Debt: $1.64M
Cash: $213.19M
Total Debt: $1.64M
Cash: $213.19M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $10.84M
Revenue: $10.84M
Revenue: $10.84M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,407.5%
Operating Income: -$152.63M
Revenue: $10.84M
Revenue: $10.84M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,419.6%
Net Income: -$153.94M
Revenue: $10.84M
Revenue: $10.84M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-100.9%
Net Income: -$153.94M
Total Equity: $203.01M
Total Equity: $203.01M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-88.0%
Operating Income: -$152.63M
Tax Rate: -1.3%
Equity: $203.01M
Total Debt: $1.64M
Cash: $213.19M
Tax Rate: -1.3%
Equity: $203.01M
Total Debt: $1.64M
Cash: $213.19M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
6.56
Current Assets: $236.66M
Current Liabilities: $36.07M
Current Liabilities: $36.07M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $435,000
Long-Term Debt: $1.21M
Total Debt: $1.64M
Total Equity: $203.01M
Long-Term Debt: $1.21M
Total Debt: $1.64M
Total Equity: $203.01M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$1.04
Revenue: $10.84M
Shares: 10,413,649
Shares: 10,413,649
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$19.49
Total Equity: $203.01M
Shares: 10,413,649
Shares: 10,413,649
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-6.96
Operating CF: -$71.53M
CapEx: -$919,000
Shares: 10,413,649
CapEx: -$919,000
Shares: 10,413,649
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $17.96
Stock Price: $17.96
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$153.94M
Net Income: -$153.94M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CBIO against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $75,000 | $10,000 | $0 | $10.8M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $1.2M | $75,000 | $10,000 | $0 | $10.8M |
| Operating Expenses | $64.6M | $47.5M | $39.3M | $49.9M | $163.5M |
| Operating Income | -$63.4M | -$47.4M | -$39.3M | -$49.9M | -$152.6M |
| Net Income | -$63.4M | -$46.7M | -$36.9M | -$48.5M | -$153.9M |
| EBITDA | -$63.2M | -$47.2M | -$39.1M | -$44.2M | -$149.7M |
| EPS | $-1.23 | $-0.89 | $-0.58 | $-1.40 | $-14.78 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $90.3M | $47.9M | $41.8M | $34.8M | $213.2M |
| Total Current Assets | $90.8M | $50.7M | $43.8M | $34.8M | $236.7M |
| Total Assets | $94.3M | $51.8M | $45.3M | $35.6M | $240.3M |
| Current Liabilities | $11.8M | $8.9M | $6.8M | $9.6M | $36.1M |
| Long-Term Debt | $0 | $0 | $0 | $37.5M | $1.2M |
| Total Liabilities | $12.7M | $8.9M | $6.9M | $51.1M | $37.3M |
| Total Equity | $81.6M | $42.9M | $38.4M | -$15.5M | $203.0M |
| Retained Earnings | -$372.9M | -$419.6M | -$456.5M | -$17.9M | -$171.8M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$71.5M |
| Capital Expenditure | $-14,943 | $-84,191 | $-21,394 | $-9,972 | $-919,000 |
| Free Cash Flow | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$72.5M |
| Acquisitions (net) | $0 | $0 | $0 | $30,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $-177,000 |
| Net Change in Cash | -$46.8M | -$42.4M | -$6.1M | -$31.1M | $178.5M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$5.6M $5.3M – $6.9M
|
$8.2M $7.8M – $10.2M
|
$16.7M $15.9M – $20.8M
|
$76.9M $73.1M – $95.5M
|
| EBITDA |
-$3.3M -$4.2M – -$3.2M
|
-$4.9M -$6.1M – -$4.7M
|
-$10.0M -$12.5M – -$9.5M
|
-$46.1M -$57.3M – -$43.8M
|
| Net Income |
-$36.3M -$44.2M – -$28.4M
|
-$36.0M -$45.1M – -$26.9M
|
-$38.9M -$51.2M – -$36.4M
|
-$35.6M -$46.8M – -$33.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -93.5% | -86.7% | -100.0% | — |
| Gross Profit Growth | -93.5% | -86.7% | -100.0% | — |
| Operating Income Growth | +25.3% | +17.1% | -27.0% | -205.9% |
| Net Income Growth | +26.4% | +21.0% | -31.5% | -217.3% |
| EBITDA Growth | +25.3% | +17.1% | -12.9% | -238.8% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-12-15 | Pinkas Jan | A-Award | 70,025.00 | $13.21 | $925,030 |
| 2025-12-15 | Pinkas Jan | A-Award | 5,000.00 | $0.00 | $0 |
| 2025-12-15 | Pinkas Jan | A-Award | 17,507.00 | $0.00 | $0 |
| 2025-12-15 | Doughty Christopher Grant | A-Award | 8,000.00 | $0.00 | $0 |
| 2025-12-15 | Doughty Christopher Grant | A-Award | 58,855.00 | $13.21 | $777,475 |
| 2025-12-15 | Doughty Christopher Grant | A-Award | 14,714.00 | $0.00 | $0 |
| 2025-12-15 | Brumm Joshua T | A-Award | 10,000.00 | $0.00 | $0 |
| 2025-12-15 | Brumm Joshua T | A-Award | 45,117.00 | $0.00 | $0 |
| 2025-12-15 | Brumm Joshua T | A-Award | 180,467.00 | $13.21 | $2.4M |
| 2025-12-15 | Scalzo Richard William | A-Award | 57,688.00 | $13.21 | $762,058 |
| 2025-12-15 | Scalzo Richard William | A-Award | 5,000.00 | $0.00 | $0 |
| 2025-12-15 | Scalzo Richard William | A-Award | 14,422.00 | $0.00 | $0 |
| 2025-12-15 | McNeill Jonathan | A-Award | 6,000.00 | $0.00 | $0 |
| 2025-12-15 | McNeill Jonathan | A-Award | 19,507.00 | $0.00 | $0 |
| 2025-12-15 | McNeill Jonathan | A-Award | 78,029.00 | $13.21 | $1.0M |
| 2025-12-15 | Im Ellie Eunkyung | A-Award | 65,190.00 | $13.21 | $861,160 |
| 2025-12-15 | Im Ellie Eunkyung | A-Award | 5,000.00 | $0.00 | $0 |
| 2025-12-15 | Im Ellie Eunkyung | A-Award | 16,298.00 | $0.00 | $0 |
| 2025-12-15 | Lynch Ryan | A-Award | 33,512.00 | $13.21 | $442,694 |
| 2025-12-15 | Lynch Ryan | A-Award | 4,000.00 | $0.00 | $0 |
No community reviews yet for CBIO.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27